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BACKGROUND: Alloanti-M was once regarded as not clinically significant, with a few exceptions in extremely rare cases. However, an increasing number of cases of severe hemolytic disease of the fetus and newborn (HDFN), resulting in fetal hydrops and recurrent abortion caused by alloanti-M, have been reported mainly in the Asian population.
STUDY DESIGN AND METHODS: Three pregnant
Chinese women with a history of abnormal pregnancy with hydrops fetalis were encountered. During this pregnancy, a series of clinical examinations and an alloantibody identification against RBCs and platelets were conducted. Intrauterine transfusion and postnatal transfusion were then performed in the fetuses. In addition, the HDFN cases caused by alloanti-M reported in different ethnic groups as well as their clinical and serologic features are also summarized.
RESULTS:
Three pregnant women were identified with an M-N+ phenotype and IgM mixed with IgG alloanti-M in serum. Their fetuses were found by ultrasound examination and cord blood testing to have severe anemia. Additionally, an M+N+ phenotype and IgG alloanti-M were detected in the cord blood of the three fetuses with titers ranging from 1:1 to 1:128. Moreover, low reticulocyte counts and negative direct antiglobulin tests were also shown in two of the fetuses. After receiving intrauterine transfusions and postnatal transfusions several times, these three fetuses eventually survived and then healthfully developed in the follow-up tracking.
CONCLUSION: Alloanti-M immunization can cause
severe HDFN with hyporegenerative anemia, often seen in the Asian population, and suppression of erythropoiesis might account for it.
H emolytic disease of the fetus and newborn (HDFN) is caused by the destruction of fetal or neonatal RBCs through maternal RBC alloantibodies that are specific against the inherited paternal RBC alloantigens of the fetus and newborn. In the Caucasian population, HDFN was a common neonatal problem dominated by D alloimmunization in the past century. However, after the introduction of routine prophylactic Rh immune globulin to D-negative women in the 1970s, the frequency of D alloimmunization is now below 0.2%. 1 However, in China and other developing countries, programs for antibody screening testing for pregnant women and the introduction of routine prophylactic Rh immune globulin injection are not well established, and antepartum treatments such as intrauterine transfusion (IUT) have been implemented only to a limited degree in few medical centers. Therefore, HDFN is still a common cause of morbidity and mortality of the fetus and newborn ABBREVIATIONS: DAT = direct agglutination test; HDFN = hemolytic disease of the fetus and newborn; IAT = indirect antiglobulin test; IUT = intrauterine transfusion; MCA-PSV = middle cerebral artery peak systolic velocity; MoM = multiple of median; RPI = reticulocyte production index. in these countries. Although D-negative phenotype is distributed with a low frequency of 3‰ to 4‰ in the Chinese population, there is a large population in China, and almost every D-negative pregnant woman encounters the potential D alloimmunization problem, as their husbands have a high probability of having a homozygous DD genotype, which results in a more than 97% probability for D-negative pregnant woman to have a D-positive fetus. 2, 3 Thus, D alloimmunization is still the most common cause of severe HDFN, which is indicated in the cases of intrauterine death and the cases treated by IUT and/or exchange transfusion after birth. 4 In addition to alloanti-D, other alloantibodies including anti-E, anti-C, anti-c, anti-M, anti-Mi(a), anti-S, and anti-Di a , have also been reported to cause severe HDFN in Chinese population. [5] [6] [7] [8] [9] [10] [11] [12] Among these, anti-M is most common next to anti-Rh, including anti-D and antibodies against E and C, c antigens.
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Alloanti-M antibodies are usually identified as an IgM antibody or a mix of IgM and IgG, which could be a kind of naturally occurring antibody. In a retrospective study with a large number of American pregnancy samples, despite alloanti-M being detected in 10% of pregnant women with positive antibody screening, no cases of mild or severe HDFN occurred.
14 In addition, in Dutch women identified with anti-M of the IgM class early in pregnancy, follow-up immunoglobulin subtypes were analyzed during the pregnancy, and a class switch to IgG had not occurred, resulting in severe outcomes. 15 All evidence from Caucasian and black populations indicates that severe HDFN cases caused by alloanti-M are very rare. However, especially in the Asian population, an increasing number of severe HDFN cases due to alloanti-M have been reported in recent decades. In our fetal medical center, alloanti-M is the most common next to anti-Rh, resulting in severe HDFN. In this study, three Chinese fetal cases with severe anemia due to maternal alloanti-M immunization were encountered and finally salvaged by a series of IUTs. In addition, 67 previous HDFN cases caused by anti-M published in English and Chinese were reviewed, and the clinical and serological characteristics of these cases were also summarized.
CASE REPORT Case 1
The patient was a 28-year-old Chinese woman at 16 weeks of gestation with a history of hydrops fetalis. Her pregnancy history was gravida 7 (including a pair of twins), para 0 with 2 induced abortions, 4 hydrops fetalis, and 1 intrauterine demise, without a history of prior blood transfusion. IgM mixed IgG alloanti-M antibodies were detected by irregular antibody screening before this pregnancy, and the titer of IgG alloanti-M was 4 at 20+4 weeks of gestation. According to the ultrasound, the peak systolic velocity in the fetal middle cerebral artery (MCA-PSV) was raised to more than 1. No specific developmental problems were found in the follow-up study within the next 2 years.
Case 3
A 24-year-old pregnant woman, gravida 5, para 2, with no history of blood transfusion, had a history of in utero fetal death with hydrops (>28 weeks of gestation), a lively fullterm baby with icterus, and two abortions. In this pregnancy, multiple fetal abnormalities, including extremely high MCA-PSV (2.63 MoM), hydroderma, hydropericardium, ascites, thickened placenta, and mild polyhydramnios, were detected by ultrasound examination at 27 weeks of gestation. IgM and IgG alloanti-M antibodies were found by maternal irregular antibody screening, and the titer of 
MATERIALS AND METHODS
Blood group typing ABO and Rh blood group typing were performed using ABO blood grouping cards (ID-DiaCell ABO, DiaClon, Bio-Rad Laboratories, DiaMed GmbH) and Rh blood grouping cards (anti-D, clone BS226; anti-C, MS-24; anti-c, MS-33; anti-E, MS-258/MS906; anti-e, MS-16/MS-21/MS-63; Bioxun Biotech). The MN blood group was typed using anti-M and anti-N reagents (Shanghai Hemo-Pharmaceutical & Biological Co., LTD) in saline using the tube method.
Antibody screening, identification, and titer detection of alloanti-M Antibody screening and identification were performed using commercial panel reagent cells (Immucor) in saline by the tube method and an indirect antiglobulin test (IAT) with gel card (DG Gel Coombs card, Diagnostic Grifols). When IgM alloantibody was detected, to confirm the existence of IgG alloantibody, dithiothreitol (0.01 mol/L) was used to destroy IgM antibody first. IgG alloantibody was determined by IAT using the tube method. The titer of IgG alloanti-M was tested by the IAT method using the reagent cells (O, D+, M + N−) in the DG Gel Coombs card after incubation at 37 C for 15 minutes.
Direct agglutination test and elution analysis
A direct agglutination test (DAT) of RBCs of the fetus or the newborn was performed using a DG gel DC scan card (Grifols), which could differentiate RBCs sensitized by IgG or the complement C3d fraction or using a gel card (DG Gel Newborn card, Grifols), which could test RBCs sensitized by IgG. DAT was performed three times in Case 1 (20th and 26th week of the fetus and the newborn) and twice in Case 2 (31st week of the fetus and the newborn).
For the fetus having a positive or even negative DAT result, the eluted solution from the RBC sample was obtained using a commercial acid elution kit (Zhanquan Biological Technology Co., LTD). The existence of IgG alloanti-M in the eluted solution was tested by the commercial panel reagent cells (Immucor) in the DG Gel Coombs card after incubation at 37 C and 4 C, respectively.
Literature review and data analysis
A literature search was conducted in online databases including PubMed for the literature in English and Wanfang Standard Database and China Academic Journal Network Publishing Database for the literature in Chinese for HDFN due to alloanti-M from 1959 to 2017. All full-text articles were included. The following data were extracted from the relevant cases: 1) the previous pregnancy history of the pregnant women; 2) ABO, Rh, and MN blood group phenotypes of the pregnant women and the fetus/infant; 3) maternal alloanti-M titer during the pregnancy; 4) fetal or neonatal DAT data; 5) the lowest hemoglobin in the fetal and neonatal period; and 6) therapeutic interventions in the fetal period and after birth. The criterion of severe anemia for the fetus is judged according to the gestational age 16 and for neonates is less than 90 g/L. 20 The statistical analysis of the data was conducted using statistical software (SPSS 22.0, SPSS, Inc.). Spearman nonparametric correlation analysis was used to calculate the correlation between lowest hemoglobin and the potential risk factors. The comparisons of rates were analyzed by the chi-squared test. A p value of less than 0.05 was regarded as statistically significant.
RESULTS

Blood group phenotyping
All three pregnant women were identified with an M−N+ phenotype; the husbands of the patients in Cases 1 and 3 had an M+N− phenotype; the husband of the patient in Case 2 had an M+N+ phenotype; and all three fetuses had an M+N+ phenotype. The ABO and Rh blood groups of the three pedigree members are shown in Table 1 . In Cases 1 and 2, ABO incompatibility also existed between the mother and the fetus.
Alloanti-M identification and titer detection
Alloanti-M was detected when the three pregnant women came to the clinic for the first time during the current pregnancy. All alloanti-M cases were a mixture of IgM and IgG. The titer of IgG alloanti-M in the serum of the three pregnant women was tested every 2 to 4 weeks throughout the pregnancy period after destroying the IgM alloanti-M. The antibody titer of the three cases always stayed stable during the pregnancy without a significant increase, which is shown in Table 1 . A comparatively lower titer was detected in Case 1 (1:4) and Case 3 (1:8) during the pregnancy.
DAT results and alloanti-M analysis in the elute
Negative DAT results were always obtained at the three times of detection of the fetus/newborn in Case 1 and the two times of detection in Case 2, even though severe anemia was observed in both cases. Although there was a negative DAT, an acid elution test was conducted in the cord blood sample in Case 1 (26th week of gestation). In the elute from RBCs of the fetus, the IgG alloanti-B was detected when the DG Gel Coombs card was incubated at 37 C, while the IgG alloanti-M could be identified only when the card was incubated at room temperature and 4 C rather than 37 C for 15 minutes.
Clinical characteristics and treatment of the fetuses affected by alloanti-M
The clinical characteristics, IUT treatment, and neonatal management of these fetuses are summarized in Table 2 . In addition to the routine testing items for anemia, the reticulocyte production index (RPI) of the fetus in Cases 1 and 2 was also calculated based on the value of reticulocyte percentage and hematocrit. The RPI is a very good parameter used to assess whether the bone marrow has an appropriate response to the anemic state. An RPI value of less than 2% with anemia indicates the existence of decreased production of reticulocytes by bone marrow, which is called hyporegenerative anemia. An RPI value of greater than 3% with anemia indicates an increased compensatory production of reticulocytes to supplement the loss of RBCs. 23 Both of the fetuses had an RPI value of 1.1%.
This result indicated the existence of severe hyporegenerative anemia caused by alloanti-M in these two fetuses.
Literature review and data analysis
A total of 64 pregnant women and their 67 fetuses/neonates with HDFN caused by alloanti-M were reviewed from 21 articles in English and 40 articles in Chinese published since 1959. The detailed data, including the pregnancy history, fetal and neonatal clinical characteristics, transfusion treatment, and the fetal outcome, are presented in Table 3 .
Including the three cases in this study, a total of 67 pregnant women and their 70 fetuses/neonates were discussed. Regarding ethnic origin, a majority of these pregnant women (59 of 67; 88.06%) were from the Asian population, including Chinese (n = 50), Indian (n = 4), Japanese (n = 3), Korean (n = 1), and Malaysian (n = 1). Among 
* The titer of anti-B in elution was 2. First GA = the first gestational age of intrauterine transfusion; GA = gestation age at birth; Hb min = the lowest hemoglobin before intrauterine transfusion; NEC = necrotizing enterocolitis; Ret = reticulocyte count before intrauterine transfusion; Ret% = reticulocyte percentage before intrauterine transfusion; RPI = reticulocyte production index, calculated according to standard procedures 22 ; Tx = times of transfusion after birth. ¶ Cases 12 and 13 were the twins in the same gravidity. ** In Cases 20, 28, 39, 50, 54, 56, and 63, the newborns received the blood transfusion or exchange blood transfusion after birth, but the accurate times were not reported in the articles. † † Cases 22, 27, and 65 were combined with ABO incompatibility. In Cases 22 and 27, the alloanti-B antibody was detected in the neonatal eluted solution. In addition, Case 65 was also combined with RhD alloimmunization, in which the titer of anti-D was 1024, but the titers of alloanti-M and alloanti-A were not reported. BPD = bronchopulmonary dysplasia; Dead = neonate death; Ex-Tx = exchange blood transfusion; G = gravidity; GA = gestation age at birth; GIB = gastrointestinal bleeding; Hb min = the lowest level of hemoglobin in fetus period and after birth; HF = hydrops fetalis; HIE = hypoxic-ischemic encephalopathy; ICH = intracranial hemorrhage; IUD = intrauterine death before 20 weeks of gestation; IUT = intrauterine transfusion; LA = late-onset anemia; N = normal; NR = not reported; PAH = pulmonary arterial hypertension; Previous history = the times of affected intrauterine demise, hydrops fetus, stillbirth, neonatal death, and neonatal icterus with HDFN; RF = respiratory failure; ROP = retinopathy of prematurity; SA = severe anemia; Stillbirth = intrauterine fetal death after 20 weeks of gestations; Tx history = blood transfusion history.
these 67 pregnant women, about half (33 of 67; 49.25%) complained of a prior history of abnormal affected pregnancy, including intrauterine demise, hydrops fetalis, stillbirth, neonatal death, and neonatal icterus with HDFN; 25 pregnant women did not have a previous history of abnormal pregnancy, while an abnormal pregnancy history was not obtained in 9 pregnant women. Among the fetuses of 14 women who suffered from alloanti-M-related HDFN in the first pregnancy, four developed severe HDFN and received treatment, including IUT (Case 19) and exchange transfusion (Case 17, 35, and 56), and they finally survived after receiving treatment. The potential factors accounting for the severity of fetal anemia, including the affected times of gravidity and the titer of alloanti-M, were evaluated using Spearman's nonparametric correlation analysis. The results showed that there was no correlation between the affected times of gravidity (p = 0.052) with the lowest level of Hb of the fetus/neonate. There was also no correlation between the maternal antibody titer with the lowest level of Hb of the fetus/neonate, regardless of whether the mother had primary immunization (p = 0.073) or was immunized with previous affected history (p = 0.266). For instance, two Swedish neonates (Cases 5 and 6) were delivered by a mother with a low titer of alloanti-M (1:1) in two separate pregnancies, and both neonates had severe anemia. After three cases without maternal and fetal blood phenotypes were excluded, there was no significant difference of the incidence of severe HDFN between alloanti-M isoimmunization with ABO incompatibility (6 of 11; 54.55%) and alloanti-M isoimmunization alone (20 of 56; 35.71%) by chisquared test (p = 0.241).
Concerning clinical treatment, one pregnant woman received only antenatal plasmapheresis to decrease the antibody titer and the fetus survived. For the 11 fetuses diagnosed with severe anemia, prenatal treatments were conducted in 10 fetuses. A total of 9 fetuses (2 Indian, 5 Chinese, 1 Korean, and 1 Swedish) received IUT, 8 of whom survived, and then received blood transfusions after birth, while the Chinese fetus in Case 21, in which the mother received IUT and antenatal plasmapheresis, was not saved in the fetal period. The Japanese fetus in Case 17 received direct immunoglobulin injection into the abdominal cavity and was successfully saved in the end. The fetus in Case 27 was diagnosed with severe anemia with hydrops at 31 weeks of gestation without receiving any antenatal treatment and was finally saved by an exchange transfusion after birth. Moreover, there were also two fetuses suffering from severe anemia, who had no antenatal treatment and did not survive. Cases 8 and 31 were stillbirths at 22 and 20 weeks of gestation, respectively. Case 30 suffered intrauterine demise at 18 weeks of gestation without any antenatal treatment. Among the remaining 55 neonates, who were not diagnosed with severe anemia and did not receive prenatal treatment in fetal period, 28 had severe anemia, and 4 of these 28 cases had neonatal death inevitably, in which 2 died as their parents gave up the treatment (Cases 32 and 64 Table 3 and Case 1 in this study) were identified as having MN and ABO HDFN, and all fetuses/neonates had severe anemia. Furthermore, the mother and fetuses/neonates of Case 65 also had alloanti-D related HDFN, and anti-D was identified in the fetus with D+ phenotype.
DISCUSSION
The MNS blood group system is the second most complex blood group system after the Rh blood group system. 82 The antigens of the MNS system are expressed on glycophorin A, glycophorin B, or a series of hybrid glycophorins. 82 Although alloanti-M is a common antibody observed in pregnant women and could also be found in the serum of individuals who have not been exposed to human erythrocytes, it is rarely clinically significant 48 and has not been regarded as an important antibody to cause HDFN, especially in Caucasian and black ethnic groups, for a long time. 14 However, in the past two decades, an increasing number of HDFN cases caused by alloanti-M have been reported, especially in the Japanese and Chinese populations. 37, 68 The literature review in this study showed that a majority of HDFN cases (59 of 67; 88.06%) caused by alloanti-M occurred in the Asian population, although only four Japanese cases were involved. There were 32 extra Japanese cases summarized in one review article, 37 which still were not involved, as their original papers were written in Japanese, and no fully detailed information about the cases was available. In the non-ABO HDFN cases reported in the Chinese population, MN alloimmunization was found second to Rh alloimmunization. 13 In the HDFN cases caused by anti-M, hyporegenerative anemia with low levels of reticulocytes and late-onset anemia were observed in the neonates. Yasuda et al. 37 reported that 55% of the affected Japanese newborns that were summarized developed late-onset anemia, and a positive correlation between the Hb level and the reticulocyte count was observed (n = 15). In our study, cord blood samples of the three fetuses (Cases 1 and 2 in this study and Case 67 listed in Table 3 , which was also previously reported by our group) were obtained before IUT at 20+3, 30+6, and 22 +6 weeks of gestation, respectively, and low reticulocyte counts and RPI values lower than 2% were shown in these three Chinese fetuses to indicate hyporegenerative anemia, which could occur as early as the second trimester of pregnancy. A series of data showed that abortion occurred more often in the first trimester, anemia occurred much earlier, and hydrops fetalis or stillbirth occurred in MN alloimmunization more than Rh alloimmunization, 37 indicating that anemia caused by alloanti-M could happen at a very early stage of pregnancy and that hyporegeneration of erythroblast rather than hemolysis should play a critical role for anemia in this stage. 83 Similar to anti-K being able to suppress erythropoiesis through inhibiting the growth of Kellpositive erythroid precusor cells, 84 there are also some primary studies to show that alloanti-M could inhibit the growth of M-positive colony-forming units in vitro, 25, 38 as M antigen is expressed on immature erythroid precursors 85, 86 as early as 9 weeks of gestation 37 and fully developed on mature RBCs at birth. In addition, the titer of alloanti-M was not related to the severity of HDFN either in the primary immunized women or in the women with a previously affected pregnancy history (both p > 0.05) in the summarized alloanti-M-related HDFN cases. This result is in accordance with previous studies, in which even the low titer of alloanti-M (1:1) could also result in stillbirth and fetal severe anemia. 27, 37 Therefore, the alloanti-M should be a high-affinity
IgG antibody that could bind to the RBCs efficiently to form antigen-antibody complexes and then be rapidly destroyed. This aspect might also explain the negative or very weak DAT observed in the fetus or neonate suffering from alloanti-M HDFN. Moreover, the reduced number of morphologically normal erythroid precursors was also observed in the bone marrow of a few infants suffering from anti-Mrelated HDNF, 25, 37 which indicates the low level or even absence of erythroblastosis that occurred in the bone marrow. Therefore, the high-affinity IgG alloanti-M could also possibly be transported into the fetal bone marrow to bind the erythroid precursors, and then the erythroid precursors coated with anti-M could be removed by phagocytosis in the bone marrow. Therefore, differing from high hyperbilirubinemia in Rh isoimmunization, hyporegenerative anemia is a characteristic of alloanti-M-related HDFN, which results in the common occurrence of longtime persistent and lateonset anemia rather than the severe jaundice observed in newborns and infants. 87 In addition, a characteristic of lowtemperature reactivity was also shown for the IgG component of alloanti-M. For instance, when the alloanti-M and the titer were tested in one Japanese newborn's serum, the levels were undetectable by saline-IAT at 37 C, 1:16 in saline at room temperature and 1:64 in saline at 4 C, while the DAT of RBCs was negative. 38 A similar reaction pattern of IgG alloanti-M was found in our study and reported by another Chinese reference lab. 49 In Case 1 of our study, in the elute from the fetal RBCs with a negative DAT, the IgG alloanti-B was detected when the DG Gel Coombs card was incubated at 37 C, while the IgG alloanti-M could be identified only when the card was incubated at room temperature and 4 C rather than 37 C. Thus, decreasing the reaction temperature for the IAT will increase the chance of detecting the IgG component of alloanti-M. How this abnormal but interesting phenomenon is explained and how the low-temperature reactivity IgG alloanti-M plays a role in the resulting severe clinical outcome still need to be clarified. In the clinic, the early occurrence of hyporegenerative anemia results in the increasing probability of early abortion and hydrops fetalis, which could even occur during the first trimester of the first pregnancy, caused by naturally developed IgG alloanti-M components (such as the 14 cases reviewed in this study). Therefore, irregular antibody screening is very important for the women with a history of multiple abortions and intrauterine fetal demise in China. Once the IgG component of alloanti-M is detected, close prenatal observation is recommended. MCA-PSV, rather than the antibody titer, should be closely monitored by ultrasound examination. However, to carry out IUT as early as the second trimester in the necessary fetuses will be a big challenge. In addition, the newborns also have more chances of having late-onset anemia and receiving multiple transfusions after birth.
Finally, unlike the protection of Rh isoimmunization by ABO incompatibility, 88, 89 whether alloanti-M isoimmunization could be alleviated by ABO incompatibility still needs more evidence to be clarified. In 11 pairs of cases with maternal-fetal ABO incompatibility reviewed in our study, 4 were confirmed with ABO HDFN by detection of alloanti-M and anti-A or anti-B in fetal/neonatal blood. No significant difference was shown about severe HDFN incidence between alloanti-M isoimmunization with ABO incompatibility and alloanti-M isoimmunization alone.
